TY - JOUR
T1 - Preparation and characterization of fibrinogen‐coated, reversibly adhesive, lecithin/cholesterol vesicles
AU - Deanglis, Ashley P.
AU - Retzinger, Gregory S.
N1 - Funding Information:
This research was supported by funds to G.S.R. from The Department of Pathology and Laboratory Medicine, the University of Cincinnati. G.S.R. thanks Ruth Mary Retzinger for inspiration.
PY - 1995/4
Y1 - 1995/4
N2 - We have developed a method for producing fibrinogen‐coated, reversibly adhesive, lecithin/cholesterol vesicles. In this method, fibrinogen, which is acylated in the presence of preformed vesicles, spontaneously incorporates into vesicular membranes. The degree of incorporation is a function of the extent of acylation of the protein. Fibrinogen‐coated vesicles aggregate in the presence of thrombin, a consequence of intervesicular fibrin formation. The rate and extent of thrombin‐initiated aggregation depend on the fibrinogen surface concentration. Once aggregated, fibrin‐coated vesicles can be dissociated by plasmin and by agents that disrupt intervesicular fibrin dimerization such as heparin and the tetrapeptide Gly‐Pro‐Arg‐Pro. Fibrinogen‐coated vesicles can be made to bind avidly to the surface of solution phase fibrin matrices and can be incorporated into solution phase fibrin clots. Fibrinogen‐coated vesicles also bind to activated platelets. We propose that fibrinogen‐coated vesicles will have practical applications as biomimetic hemostatic agents and as vehicles for the fibrin‐specific targeting of drugs and other molecules.
AB - We have developed a method for producing fibrinogen‐coated, reversibly adhesive, lecithin/cholesterol vesicles. In this method, fibrinogen, which is acylated in the presence of preformed vesicles, spontaneously incorporates into vesicular membranes. The degree of incorporation is a function of the extent of acylation of the protein. Fibrinogen‐coated vesicles aggregate in the presence of thrombin, a consequence of intervesicular fibrin formation. The rate and extent of thrombin‐initiated aggregation depend on the fibrinogen surface concentration. Once aggregated, fibrin‐coated vesicles can be dissociated by plasmin and by agents that disrupt intervesicular fibrin dimerization such as heparin and the tetrapeptide Gly‐Pro‐Arg‐Pro. Fibrinogen‐coated vesicles can be made to bind avidly to the surface of solution phase fibrin matrices and can be incorporated into solution phase fibrin clots. Fibrinogen‐coated vesicles also bind to activated platelets. We propose that fibrinogen‐coated vesicles will have practical applications as biomimetic hemostatic agents and as vehicles for the fibrin‐specific targeting of drugs and other molecules.
UR - http://www.scopus.com/inward/record.url?scp=0028958391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028958391&partnerID=8YFLogxK
U2 - 10.1002/jps.2600840404
DO - 10.1002/jps.2600840404
M3 - Article
C2 - 7629727
AN - SCOPUS:0028958391
SN - 0022-3549
VL - 84
SP - 399
EP - 403
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 4
ER -